LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Axsome Therapeutics Inc

Closed

SectorHealthcare

104.06 -1.96

Overview

Share price change

24h

Current

Min

103.6

Max

106.24

Key metrics

By Trading Economics

Income

15M

-59M

Sales

2.7M

121M

EPS

-1.216

Profit margin

-48.914

Employees

712

EBITDA

14M

-57M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+68.69% upside

Dividends

By Dow Jones

Next Earnings

4 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-62M

5.4B

Previous open

106.02

Previous close

104.06

News Sentiment

By Acuity

77%

23%

361 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Axsome Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Jun 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380 Million

13 Jun 2025, 23:50 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 Jun 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 Jun 2025, 23:09 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 Jun 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 Jun 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380M

13 Jun 2025, 22:04 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 Jun 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 Jun 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Bunge: Outside Date Extended to July 3

13 Jun 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 Jun 2025, 21:34 UTC

Acquisitions, Mergers, Takeovers

Bunge Gets Mexico Approval for Viterra Deal

13 Jun 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bunge Gets China Approval for Viterra Deal

13 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 Jun 2025, 20:45 UTC

Acquisitions, Mergers, Takeovers

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 Jun 2025, 20:34 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 Jun 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 Jun 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 Jun 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 Jun 2025, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 Jun 2025, 19:12 UTC

Market Talk

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 Jun 2025, 19:04 UTC

Market Talk

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 Jun 2025, 18:54 UTC

Market Talk

Correction to Gold Settles Market Talk

13 Jun 2025, 18:01 UTC

Market Talk

Gold Settles at Record High -- Market Talk

13 Jun 2025, 17:40 UTC

Market Talk

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 Jun 2025, 17:21 UTC

Market Talk

Dollar Index, Commodities Rise -- Market Talk

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

13 Jun 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Peer Comparison

Price change

Axsome Therapeutics Inc Forecast

Price Target

By TipRanks

68.69% upside

12 Months Forecast

Average 179.23 USD  68.69%

High 210 USD

Low 148 USD

Based on 16 Wall Street analysts offering 12 month price targets forAxsome Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

107.24 / 112.29Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

361 / 380 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.